Text Size:AAA

肿瘤抗原

Tumor Antigen

Product CategoriesProteinsAntibodiesELISA KitscDNA Clones
Number of Products

肿瘤抗原 Related Products Index

肿瘤抗原 Related Products by Product Type

肿瘤抗原 By Species

肿瘤抗原 by Signaling Pathways

肿瘤抗原 Background

The term "tumor antigen" has been given a new and much more precise definition as a result of important developments in immunology over the last decade, particularly in the area of antigen presentation and antigen recognition. Tumor antigen must be recognized by specific immune effector cells and/or antibodies and be produced by tumor cells. Among the tumor antigens, some may be tumor specific while others may also be expressed by normal tissues. Cancer cells have accumulated mutations that are possibly recognized as non-self by the immune system. These mutations are different for each tumor. Sometimes, these mutations trigger an immune response. These antigens are referred to as Specific Tumor Antigens (STA). STAs can be derived from intracellular or extracellular proteins, and can be presented in a way that they can be recognized by T-cells. Cancer cells also produce antigens that are sometimes common in a certain subpopulation of tumors. These antigens are considered as Common Tumor Antigens (CTA). CTAs can be used as a marker to categorize the tumor, or to monitor disease progression. Usually, a CTA is exposed to the extracellular environment and can be recognized by antibodies.

肿瘤抗原 References

  1. Sarnow P, et al. (1982) Adenovirus E1b-58kd tumor antigen and SV40 large tumor antigen are physically associated with the same 54 kd cellular protein in transformed cells. Cell. 28(2): 387-94.
  2. DeCaprio JA, et al. (1988) SV40 large tumor antigen forms a specific complex with the product of the retinoblastoma susceptibility gene. Cell. 54(2): 275-83.
  3. Kato H, et al. (1977) Radioimmunoassay for tumor antigen of human cervical squamous cell carcinoma. Cancer. 40(4): 1621-8.